Form 4: Monopar Director Klausner Acquires 7,710 Shares

Monopar Therapeutics Director Arthur J. Klausner reported acquiring 7,710 shares of common stock through a pro rata distribution.

Summary

• Arthur J. Klausner, a Director of Monopar Therapeutics (MNPR), acquired 7,710 shares of the company's common stock.
• The transaction occurred on December 16, 2025, and was a pro rata distribution from Gem Pharmaceuticals, LLC, where Klausner is a non-managing member.
• The acquisition price per share was $0.
• Following this transaction, Arthur J. Klausner beneficially owns 13,883 shares of Monopar Therapeutics common stock.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director, even through a distribution, generally indicates alignment of interests with shareholders, which is a positive signal. However, it is not an open market purchase, which would typically convey stronger direct confidence.

Positives

• Increased insider ownership by a director, which can signal alignment of interests with shareholders.

Negatives

• The acquisition was a distribution rather than an open market purchase, which might be interpreted as a less direct vote of confidence compared to a cash purchase.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider transactions, such as the acquisition of shares by a director, are closely monitored by investors as they can provide insights into management's confidence in the company's future prospects. While a distribution differs from an open market purchase, any increase in insider holdings is generally viewed as a positive signal of alignment with shareholder interests.

Related Party Transactions

• The acquisition of shares by Arthur J. Klausner was a pro rata distribution from Gem Pharmaceuticals, LLC, of which he is a non-managing member. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive sign of management's commitment and belief in the company's value.

Key Dates

Keywords

Monopar Therapeutics, MNPR, Arthur J. Klausner, Insider Transaction, Form 4, Director Share Acquisition, Common Stock, Beneficial Ownership